The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

Nonfiction, Health & Well Being, Medical, Specialties, Pharmacy, Science & Nature, Technology
Cover of the book The Challenge of CMC Regulatory Compliance for Biopharmaceuticals by John Geigert, Springer New York
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: John Geigert ISBN: 9781461469162
Publisher: Springer New York Publication: July 8, 2014
Imprint: Springer Language: English
Author: John Geigert
ISBN: 9781461469162
Publisher: Springer New York
Publication: July 8, 2014
Imprint: Springer
Language: English

This book highlights the challenges facing quality assurance/quality control (QA/QC) in today's biopharmaceutical environment and presents the strategic importance and value generated by QA/QC for their involvement in control of manufacturing. It will put into perspective the need for a graded approach to QA/QC from early clinical trials through market approval. Since the first edition published in 2004, there have been more than 50 new regulatory guidances released by the Food and Drug Administration (FDA), European Medicines Agency (EMA) and ICH that affect the CMC regulatory compliance of biopharmaceuticals; also the application of biosimilars has been developed in Europe and is under development in the USA. The revised update will be broadened to include not only biopharmaceuticals (biotech drugs) but also other biologics (vaccines, cell therapy, plasma-derived proteins, etc.)

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

This book highlights the challenges facing quality assurance/quality control (QA/QC) in today's biopharmaceutical environment and presents the strategic importance and value generated by QA/QC for their involvement in control of manufacturing. It will put into perspective the need for a graded approach to QA/QC from early clinical trials through market approval. Since the first edition published in 2004, there have been more than 50 new regulatory guidances released by the Food and Drug Administration (FDA), European Medicines Agency (EMA) and ICH that affect the CMC regulatory compliance of biopharmaceuticals; also the application of biosimilars has been developed in Europe and is under development in the USA. The revised update will be broadened to include not only biopharmaceuticals (biotech drugs) but also other biologics (vaccines, cell therapy, plasma-derived proteins, etc.)

More books from Springer New York

Cover of the book Psychology, Religion, and the Nature of the Soul by John Geigert
Cover of the book Mental Modeling Approach by John Geigert
Cover of the book Evolutionary Foundations of Equilibria in Irrational Markets by John Geigert
Cover of the book Link Mining: Models, Algorithms, and Applications by John Geigert
Cover of the book Immunologic Signatures of Rejection by John Geigert
Cover of the book Crohn's Disease and Ulcerative Colitis by John Geigert
Cover of the book Finnie's Notes on Fracture Mechanics by John Geigert
Cover of the book Functional Metal Oxide Nanostructures by John Geigert
Cover of the book Protein Tyrosine Phosphatases in Cancer by John Geigert
Cover of the book Analysis and Modeling of Coordinated Multi-neuronal Activity by John Geigert
Cover of the book The Quality of Measurements by John Geigert
Cover of the book Dynamic Behavior of Materials, Volume 1 by John Geigert
Cover of the book Quantum-Limit Spectroscopy by John Geigert
Cover of the book Identity and Intimacy in Marriage by John Geigert
Cover of the book Prospects of Heart Surgery by John Geigert
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy